BFM
RVMD icon

Boothbay Fund Management’s Revolution Medicines RVMD Stock Holding History

Boothbay Fund Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
55,400
+5,100
+10% +$745K 0.14% 153
2026
Q1 		$4.89M Buy
50,300
+23,900
+91% +$2.41M 0.06% 329
2025
Q4 		$2.1M Sell
26,400
-8,100
-23% -$531K 0.03% 548
2025
Q3 		$1.61M Buy
+34,500
New +$1.35M 0.02% 652
2021
Q2 		– Sell
-179
Closed -$821K – 2077
2021
Q1 		$821K Buy
+179
New +$8.03K 0.03% 702

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Boothbay Fund Management's RVMD Position: Q2 2026 in Review

Boothbay Fund Management increased its Revolution Medicines (RVMD) stake by 6.2% in Q2 2026, buying an estimated $3.97M and bringing the position to 465,787 shares worth $87.2M. The position accounts for 1.15% of the portfolio, ranked #3.

Boothbay Fund Management first reported a position in RVMD in Q1 2025 and has held it in 6 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Boothbay Fund Management held 465,787 shares of Revolution Medicines worth $87.2M as of Q2 2026.
  • Boothbay Fund Management bought 27,192 Revolution Medicines shares in Q2 2026, an estimated $3.97M.
  • Revolution Medicines made up 1.15% of Boothbay Fund Management's portfolio in Q2 2026, its #3 holding.
  • Boothbay Fund Management first reported a position in Revolution Medicines in Q1 2025 and has held it in 6 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.